Quantification of cerivastatin toxicity supports organismal performance assays as an effective tool during pharmaceutical safety assessment

A major problem in pharmaceutical development is that adverse effects remain undetected during preclinical and clinical trials, but are later revealed after market release when prescribed to many patients. We have developed a fitness assay known as the organismal performance assay (OPA), which evalu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Evol Appl
Autors principals: Gaukler, Shannon M., Ruff, James S., Galland, Tessa, Underwood, Tristan K., Kandaris, Kirstie A., Liu, Nicole M., Morrison, Linda C., Veranth, John M., Potts, Wayne K.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2016
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4869410/
https://ncbi.nlm.nih.gov/pubmed/27247619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/eva.12365
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars